![]() |
|
||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Mon., Apr. 28, 10:45 AM
|
This Slide: #2 of 25 |
Announced:
4/24/2025
Stock Split:
1 for 30
Record Date:
4/25/2025
Pay Date:
4/28/2025
XFOR Optionable?:
Yes
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4).
XFOR SEC Filing Email Alerts ServiceXFOR Detailed Information Page & Split History »
|
Open the XFOR Page at The Online Investor (in a new window) »
![]() ![]() Get SEC Filing Alerts Get Dividend Alerts ![]() ![]() |
![]() Strong Buy (4.00 out of 4) 77th percentile
(ranked higher than approx. 77% of all stocks covered)
Analysts' Target Price: XFOR Stock Forecast Based on Zacks ABR data; powered by Xignite ![]() |